This week’s buy-write trade is on Intra-Cellular Therapies (ITCI). The stock dropped some 25% in a knee jerk fashion earlier last week as it disclosed some trial results that disappointed investors. The shares are recovered a bit, but still appear oversold given the key catalyst the company has on the horizon. We take a look at this week's news, why there should be upside in this name in coming months and an options strategy that can set up a great potential return while mitigating considerable downside risk.
DOWNLOAD FREE REPORT AT → https://www.bretjenseninvests.com/freereports